Authors:
F Skoulidis, LD Cassidy, V Pisupati, JG Jonasson, H Bjarnason, JE Eyfjord, FA Karreth, M Lim, LM Barber, SA Clatworthy, SE Davies, KP Olive, DA Tuveson, AR Venkitaraman
Journal name: 
Cancer Cell
Citation info: 
18(5):499-509
Abstract: 
Inherited heterozygous BRCA2 mutations predispose carriers to tissue-specific cancers, but somatic deletion of the wild-type allele is considered essential for carcinogenesis. We find in a murine model of familial pancreatic cancer that germline heterozygosity for a pathogenic Brca2 truncation suffices to promote pancreatic ductal adenocarcinomas (PDACs) driven by Kras(G12D), irrespective of Trp53 status. Unexpectedly, tumor cells retain a functional Brca2 allele. Correspondingly, three out of four PDACs from patients inheriting BRCA2(999del5) did not exhibit loss-of-heterozygosity (LOH). Three tumors from these patients displaying LOH were acinar carcinomas, which also developed only in mice with biallelic Brca2 inactivation. We suggest a revised model for tumor suppression by BRCA2 with implications for the therapeutic strategy targeting BRCA2 mutant cancer cells.
DOI: 
http://doi.org/10.1016/j.ccr.2010.10.015
Research group: 
Tuveson Group
E-pub date: 
31 Oct 2010